//Generics --> https://generics.citeline.com

Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sandoz starts with Zessly in Germany

Executive Summary

Germany has become the launch market for Sandoz’Zessly (infliximab) biosimilar after the company’s Hexal affiliate introduced the rival to Merck Sharp & Dohme’s (MSD’s) Remicade on 15 November. Launch list prices for Zessly 100mg powder for concentrate range from €705.29 (US$804.00) for one 100mg vial to €3,467.28 for a pack of five, representing a modest 5% discount to MSD’s list price for Remicade.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB001500

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel